A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214-02 to Rabeprazole in healthy volunteers.
This study is to compare the safety, pharmacokinetic characteristics and pharmacodynamics characteristics of AD-214-02 compared with administration of Rabeprazole in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
43
1 tablet administered before the breakfast during 7 days
1 tablet administered before the breakfast during 7 days
Seoul National University Hospital
Seoul, South Korea
AUCtau,ss(Area under the plasma drug concentration-time curve)
Evaluation PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Gastric acidity(After 7days of repeated administration, The change of integrated gastric acidity)
Evaluation PD Rabeprazole after multiple dose
Time frame: Day1 24hours pH monitoring, Day7 24hours pH monitoring, Day22 24hours monitoring, Day28 24hours pH monitoring
AUCtau(Area under the plasma drug concentration-time curve)
Evaluation PK Rabeprazole after single dose
Time frame: Day1
Cmax(Maximum concentration of drug in plasma)
Evaluation PK Rabeprazole after single dose
Time frame: Day1
Tmax(Time to maximum plasma concentration)
Evaluation PK Rabeprazole after single dose
Time frame: Day1
t1/2(Terminal elimination half-life)
Evaluation PK Rabeprazole after single dose
Time frame: Day1
Cmax,ss(Maximum concentration of drug in plasma at steady state)
Evaluation PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
Tmax,ss(Time to maximum plasma concentration at steady state)
Evaluation PK Rabeprazole after multiple dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From Day 1 up to Day 29
t1/2,ss(Terminal elimination half-life at steady state)
Evaluation PK Rabeprazole after multiple dose
Time frame: From Day 1 up to Day 29
After the first dose and 7 days of repeated dosing, Percentage of time to maintain gastric pH 4.0 or higher for 24 hours
Evaluation PD Rabeoprazoke
Time frame: Day1 24hours pH monitoring, Day7 24hours pH monitoring, Day22 24hours monitoring, Day28 24hours pH monitoring
After the first administration and 7 days of repeated administration, The median pH measured for 24 hours
Evaluation PD Rabeoprazoke
Time frame: Day1 24hours pH monitoring, Day7 24hours pH monitoring, Day22 24hours monitoring, Day28 24hours pH monitoring